Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: Ubrogepant Clear all

Conditions: Overactive Bladder, Bladder Pain Syndrome, Migraine Disorders, Overactive Bladder Syndrome, Overactive Detrusor, Migraine, Interstitial Cystitis
Interventions: Ubrogepant, Rimegepant, Atogepant, Eptinezumab, Fremanezumab, Galcanezumab, Erenumab, Botulinum toxin A; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Migraine
Interventions: Ubrogepant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 109
States / cities: Huntsville, Alabama • Saraland, Alabama • Little Rock, Arkansas + 92 more

Conditions: Migraine
Interventions: Ubrogepant, Placebo for Ubrogepant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 103
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 92 more

Conditions: Migraine
Interventions: Not listed
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Aliso Viejo, California • Naperville, Illinois • Grand Island, Nebraska

Conditions: Migraine
Interventions: Ubrogepant, Erenumab, Galcanezumab; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 2
States / cities: Springfield, Missouri • West Bend, Wisconsin

Conditions: Migraine
Interventions: Ubrogepant 100 mg, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 73
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 65 more

Conditions: Episodic Migraine
Interventions: Atogepant, Ubrogepant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Oceanside, California + 34 more

Conditions: Healthy Volunteers
Interventions: Atogepant, Ubrogepant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Springfield, Missouri • San Antonio, Texas • Salt Lake City, Utah

Conditions: Healthy Volunteer
Interventions: Ubrogepant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Migraine, With or Without Aura
Interventions: Ubrogepant, Placebo-matching Ubrogepant, Usual Care; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 76 Years
Enrollment: 1,254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 177
States / cities: Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 137 more

Conditions: Migraine
Interventions: Ubrogepant, Placebo-Matching Ubrogepant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 1,059 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 123
States / cities: Huntsville, Alabama • Saraland, Alabama • Phoenix, Arizona + 101 more

Conditions: Migraine
Interventions: Ubrogepant, Lu AG09222, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Orlando, Florida • Atlanta, Georgia • Austin, Texas + 1 more

Conditions: Migraine, With or Without Aura
Interventions: Ubrogepant, Placebo-matching Ubrogepant; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,686 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 109
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 91 more

Conditions: Migraine, With or Without Aura
Interventions: Ubrogepant, Placebo-matching Ubrogepant; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 90
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 77 more

Conditions: Migraine
Interventions: Atogepant, Ubrogepant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 3
States / cities: Orlando, Florida • Springfield, Missouri • West Bend, Wisconsin

Conditions: Migraine
Interventions: Not listed
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 391 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Headache, Migraine
Interventions: Ubrogepant 50 MG [Ubrelvy], Ubrogepant 100 MG [Ubrelvy]; Drug
Lead sponsor: Chicago Headache Center & Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Chicago, Illinois • Naperville, Illinois

Conditions: Migraine
Interventions: Not listed
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,884 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2036
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Migraine Medication Effects on Urinary Symptoms

Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks

Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine

Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants

Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine

Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers

Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult Participants

An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine

Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine

Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine

Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine

An Observational Study to Assess Change in Disease Activity When Ubrogepant Tablets Are Combined With Atogepant Tablets to Treat Migraine in Adult Participants

Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodies

Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy